Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
= 33 34 33 34 O
750 35 38 35 38 B-lower_bound
/ 38 39 38 39 I-lower_bound
mcl 39 42 39 42 I-lower_bound

Adult 0 5 43 48 B-cancer
T 6 7 49 50 I-cancer
- 7 8 50 51 I-cancer
cell 8 12 51 55 I-cancer
lymphoma 13 21 56 64 I-cancer
/ 21 22 64 65 I-cancer
leukemia 22 30 65 73 I-cancer
( 31 32 74 75 I-cancer
ATLL 32 36 75 79 I-cancer
) 36 37 79 80 I-cancer

Age 0 3 81 84 B-age
> 4 5 85 86 O
= 5 6 86 87 O
18 7 9 88 90 B-lower_bound
years 10 15 91 96 I-lower_bound
to 16 18 97 99 O
< 19 20 100 101 O
60 21 23 102 104 B-upper_bound
years 24 29 105 110 I-upper_bound

All 0 3 111 114 O
patients 4 12 115 123 O
must 13 17 124 128 O
agree 18 23 129 134 B-contraception_consent
to 24 26 135 137 I-contraception_consent
use 27 30 138 141 I-contraception_consent
effective 31 40 142 151 I-contraception_consent
contraception 41 54 152 165 I-contraception_consent
while 55 60 166 171 O
on 61 63 172 174 O
study 64 69 175 180 O

All 0 3 181 184 O
study 4 9 185 190 O
participants 10 22 191 203 O
must 23 27 204 208 O
be 28 30 209 211 O
registered 31 41 212 222 O
into 42 46 223 227 O
the 47 50 228 231 O
mandatory 51 60 232 241 O
Revlimid 61 69 242 250 B-treatment
REMS 70 74 251 255 I-treatment
® 74 75 255 256 I-treatment
program 76 83 257 264 I-treatment
, 83 84 264 265 O
and 85 88 266 269 O
be 89 91 270 272 O
willing 92 99 273 280 O
and 100 103 281 284 O
able 104 108 285 289 O
to 109 111 290 292 O
comply 112 118 293 299 O
with 119 123 300 304 O
the 124 127 305 308 O
requirements 128 140 309 321 O
of 141 143 322 324 O
the 144 147 325 328 O
REMS 148 152 329 333 O
® 152 153 333 334 O
program 154 161 335 342 O

Anaplastic 0 10 343 353 B-cancer
large 11 16 354 359 I-cancer
cell 17 21 360 364 I-cancer
lymphoma 22 30 365 373 I-cancer

Anaplastic 0 10 374 384 B-cancer
large 11 16 385 390 I-cancer
cell 17 21 391 395 I-cancer
lymphoma 22 30 396 404 I-cancer
, 30 31 404 405 O
ALK 32 35 406 409 B-treatment
- 35 36 409 410 O
positive 36 44 410 418 O

Anaplastic 0 10 419 429 B-cancer
large 11 16 430 435 I-cancer
- 16 17 435 436 I-cancer
cell 17 21 436 440 I-cancer
lymphoma 22 30 441 449 I-cancer
, 30 31 449 450 O
primary 32 39 451 458 O
cutaneous 40 49 459 468 O
type 50 54 469 473 O

Angioimmunoblastic 0 18 474 492 B-cancer
T 19 20 493 494 I-cancer
- 20 21 494 495 I-cancer
cell 21 25 495 499 I-cancer
lymphoma 26 34 500 508 I-cancer

Aspartate 0 9 509 518 B-clinical_variable
aminotransferase 10 26 519 535 I-clinical_variable
( 27 28 536 537 I-clinical_variable
AST 28 31 537 540 I-clinical_variable
) 31 32 540 541 I-clinical_variable
( 33 34 542 543 O
serum 34 39 543 548 B-clinical_variable
glutamic 40 48 549 557 I-clinical_variable
oxaloacetic 49 60 558 569 I-clinical_variable
transaminase 61 73 570 582 I-clinical_variable
[ 74 75 583 584 I-clinical_variable
SGOT 75 79 584 588 I-clinical_variable
] 79 80 588 589 I-clinical_variable
) 80 81 589 590 O
and 82 85 591 594 O
alanine 86 93 595 602 B-clinical_variable
aminotransferase 94 110 603 619 I-clinical_variable
( 111 112 620 621 I-clinical_variable
ALT 112 115 621 624 I-clinical_variable
) 115 116 624 625 I-clinical_variable
( 117 118 626 627 O
serum 118 123 627 632 B-clinical_variable
pyruvate 124 132 633 641 I-clinical_variable
glutamate 133 142 642 651 I-clinical_variable
transaminase 143 155 652 664 I-clinical_variable
[ 156 157 665 666 I-clinical_variable
SPGT 157 161 666 670 I-clinical_variable
] 161 162 670 671 I-clinical_variable
) 162 163 671 672 O
= 164 165 673 674 O
< 165 166 674 675 O
3 167 168 676 677 B-upper_bound
x 169 170 678 679 I-upper_bound
ULN 171 174 680 683 I-upper_bound

Cardiac 0 7 684 691 B-chronic_disease
arrhythmia 8 18 692 702 I-chronic_disease

Creatinine 0 10 703 713 B-clinical_variable
= 11 12 714 715 O
< 12 13 715 716 O
2 14 15 717 718 B-upper_bound
x 16 17 719 720 I-upper_bound
ULN 18 21 721 724 I-upper_bound

Enteropathy 0 11 725 736 B-cancer
- 11 12 736 737 I-cancer
type 12 16 737 741 I-cancer
T 17 18 742 743 I-cancer
- 18 19 743 744 I-cancer
cell 19 23 744 748 I-cancer
lymphoma 24 32 749 757 I-cancer

Extranodal 0 10 758 768 B-cancer
natural 11 18 769 776 I-cancer
killer 19 25 777 783 I-cancer
( 26 27 784 785 I-cancer
NK)/T 27 32 785 790 I-cancer
- 32 33 790 791 I-cancer
cell 33 37 791 795 I-cancer
lymphoma 38 46 796 804 I-cancer
, 46 47 804 805 I-cancer
nasal 48 53 806 811 I-cancer
type 54 58 812 816 I-cancer

FCPB 0 4 817 821 O
must 5 9 822 826 O
have 10 14 827 831 O
a 15 16 832 833 O
negative 17 25 834 842 B-pregnancy
urine 26 31 843 848 I-pregnancy
or 32 34 849 851 I-pregnancy
serum 35 40 852 857 I-pregnancy
pregnancy 41 50 858 867 I-pregnancy
test 51 55 868 872 O
within 56 62 873 879 O
7 63 64 880 881 B-upper_bound
days 65 69 882 886 I-upper_bound
prior 70 75 887 892 I-upper_bound
to 76 78 893 895 O
registration 79 91 896 908 O
, 91 92 908 909 O
and 93 96 910 913 O
be 97 99 914 916 O
willing 100 107 917 924 O
to 108 110 925 927 O
adhere 111 117 928 934 O
to 118 120 935 937 O
the 121 124 938 941 O
scheduled 125 134 942 951 O
pregnancy 135 144 952 961 O
testing 145 152 962 969 O
as 153 155 970 972 O
required 156 164 973 981 O
in 165 167 982 984 O
the 168 171 985 988 O
Revlimid 172 180 989 997 O
Risk 181 185 998 1002 O
Evaluation 186 196 1003 1013 O
and 197 200 1014 1017 O
Mitigation 201 211 1018 1028 O
Strategies 212 222 1029 1039 O
( 223 224 1040 1041 O
REMS 224 228 1041 1045 O
® 228 229 1045 1046 O
) 229 230 1046 1047 O
program 231 238 1048 1055 O

Females 0 7 1056 1063 B-gender
of 8 10 1064 1066 O
childbearing 11 23 1067 1079 O
potential 24 33 1080 1089 O
( 34 35 1090 1091 O
FCBP 35 39 1091 1095 O
) 39 40 1095 1096 O
must 41 45 1097 1101 O
either 46 52 1102 1108 O
commit 53 59 1109 1115 B-contraception_consent
to 60 62 1116 1118 I-contraception_consent
continued 63 72 1119 1128 I-contraception_consent
abstinence 73 83 1129 1139 I-contraception_consent
from 84 88 1140 1144 I-contraception_consent
heterosexual 89 101 1145 1157 I-contraception_consent
intercourse 102 113 1158 1169 I-contraception_consent
or 114 116 1170 1172 O
begin 117 122 1173 1178 B-contraception_consent
TWO 123 126 1179 1182 I-contraception_consent
acceptable 127 137 1183 1193 I-contraception_consent
methods 138 145 1194 1201 I-contraception_consent
of 146 148 1202 1204 I-contraception_consent
birth 149 154 1205 1210 I-contraception_consent
control 155 162 1211 1218 I-contraception_consent
: 162 163 1218 1219 O
one 164 167 1220 1223 O
highly 168 174 1224 1230 O
effective 175 184 1231 1240 O
method 185 191 1241 1247 O
and 192 195 1248 1251 O
one 196 199 1252 1255 O
additional 200 210 1256 1266 O
effective 211 220 1267 1276 O
method 221 227 1277 1283 O
AT 228 230 1284 1286 O
THE 231 234 1287 1290 O
SAME 235 239 1291 1295 O
TIME 240 244 1296 1300 O
, 244 245 1300 1301 O
at 246 248 1302 1304 O
least 249 254 1305 1310 O
28 255 257 1311 1313 B-lower_bound
days 258 262 1314 1318 I-lower_bound
before 263 269 1319 1325 I-lower_bound
starting 270 278 1326 1334 O
lenalidomide 279 291 1335 1347 B-treatment
, 291 292 1347 1348 O
during 293 299 1349 1355 O
lenalidomide 300 312 1356 1368 B-treatment
therapy 313 320 1369 1376 I-treatment
, 320 321 1376 1377 O
during 322 328 1378 1384 O
dose 329 333 1385 1389 O
interruptions 334 347 1390 1403 O
, 347 348 1403 1404 O
and 349 352 1405 1408 O
for 353 356 1409 1412 O
at 357 359 1413 1415 O
least 360 365 1416 1421 O
28 366 368 1422 1424 O
days 369 373 1425 1429 O
following 374 383 1430 1439 O
discontinuation 384 399 1440 1455 O
of 400 402 1456 1458 O
lenalidomide 403 415 1459 1471 O
therapy 416 423 1472 1479 O

Hemoglobin 0 10 1480 1490 B-clinical_variable
> 11 12 1491 1492 O
= 12 13 1492 1493 O
8 14 15 1494 1495 B-lower_bound
g 16 17 1496 1497 I-lower_bound
/ 17 18 1497 1498 I-lower_bound
dl 18 20 1498 1500 I-lower_bound

Hepatosplenic 0 13 1501 1514 B-cancer
gamma 14 19 1515 1520 I-cancer
- 19 20 1520 1521 I-cancer
delta 20 25 1521 1526 I-cancer
T 26 27 1527 1528 I-cancer
- 27 28 1528 1529 I-cancer
cell 28 32 1529 1533 I-cancer
lymphoma 33 41 1534 1542 I-cancer

Histologically 0 14 1543 1557 O
confirmed 15 24 1558 1567 O
diagnosis 25 34 1568 1577 O
of 35 37 1578 1580 O
PTCL 38 42 1581 1585 B-cancer
( 43 44 1586 1587 O
using 44 49 1587 1592 O
the 50 53 1593 1596 O
most 54 58 1597 1601 O
recent 59 65 1602 1608 O
edition 66 73 1609 1616 O
of 74 76 1617 1619 O
the 77 80 1620 1623 O
World 81 86 1624 1629 O
Health 87 93 1630 1636 O
Organization 94 106 1637 1649 O
[ 107 108 1650 1651 O
WHO 108 111 1651 1654 O
] 111 112 1654 1655 O
Classification 113 127 1656 1670 O
of 128 130 1671 1673 O
Tumors 131 137 1674 1680 O
of 138 140 1681 1683 O
Hematopoietic 141 154 1684 1697 O
and 155 158 1698 1701 O
Lymphoid 159 167 1702 1710 O
Tissues 168 175 1711 1718 O
as 176 178 1719 1721 O
guidance 179 187 1722 1730 O
) 187 188 1730 1731 O

Mycosis 0 7 1732 1739 B-cancer
fungoides 8 17 1740 1749 I-cancer
/ 17 18 1749 1750 O
Sezary 18 24 1750 1756 B-cancer
syndrome 25 33 1757 1765 I-cancer

NK 0 2 1766 1768 B-cancer
- 2 3 1768 1769 I-cancer
cell 3 7 1769 1773 I-cancer
leukemia 8 16 1774 1782 I-cancer

Ongoing 0 7 1783 1790 O
or 8 10 1791 1793 O
active 11 17 1794 1800 B-chronic_disease
infection 18 27 1801 1810 I-chronic_disease

Patients 0 8 1811 1819 O
must 9 13 1820 1824 O
be 14 16 1825 1827 O
free 17 21 1828 1832 O
of 22 24 1833 1835 O
any 25 28 1836 1839 O
prior 29 34 1840 1845 O
malignancies 35 47 1846 1858 B-cancer
for 48 51 1859 1862 O
> 52 53 1863 1864 O
= 53 54 1864 1865 O
1 55 56 1866 1867 B-lower_bound
year 57 61 1868 1872 I-lower_bound

Patients 0 8 1873 1881 O
must 9 13 1882 1886 O
have 14 18 1887 1891 O
adequate 19 27 1892 1900 O
organ 28 33 1901 1906 O
and 34 37 1907 1910 O
marrow 38 44 1911 1917 O
function 45 53 1918 1926 O
( 54 55 1927 1928 O
documented 55 65 1928 1938 O
within 66 72 1939 1945 O
14 73 75 1946 1948 B-upper_bound
days 76 80 1949 1953 I-upper_bound
prior 81 86 1954 1959 I-upper_bound
to 87 89 1960 1962 O
registration 90 102 1963 1975 O
) 102 103 1975 1976 O

Patients 0 8 1977 1985 O
must 9 13 1986 1990 O
have 14 18 1991 1995 O
an 19 21 1996 1998 O
Eastern 22 29 1999 2006 B-clinical_variable
Cooperative 30 41 2007 2018 I-clinical_variable
Oncology 42 50 2019 2027 I-clinical_variable
Group 51 56 2028 2033 I-clinical_variable
( 57 58 2034 2035 I-clinical_variable
ECOG 58 62 2035 2039 I-clinical_variable
) 62 63 2039 2040 I-clinical_variable
performance 64 75 2041 2052 I-clinical_variable
status 76 82 2053 2059 I-clinical_variable
= 83 84 2060 2061 O
< 84 85 2061 2062 O
2 86 87 2063 2064 B-upper_bound

Patients 0 8 2065 2073 O
must 9 13 2074 2078 O
have 14 18 2079 2083 O
bi 19 21 2084 2086 B-clinical_variable
- 21 22 2086 2087 I-clinical_variable
dimensionally 22 35 2087 2100 I-clinical_variable
measurable 36 46 2101 2111 I-clinical_variable
disease 47 54 2112 2119 I-clinical_variable
( 55 56 2120 2121 O
> 56 57 2121 2122 O
= 57 58 2122 2123 O
1 59 60 2124 2125 B-lower_bound
cm 61 63 2126 2128 I-lower_bound
) 63 64 2128 2129 O
by 65 67 2130 2132 O
CT 68 70 2133 2135 B-treatment
imaging 71 78 2136 2143 O

Patients 0 8 2144 2152 O
must 9 13 2153 2157 O
not 14 17 2158 2161 O
have 18 22 2162 2166 O
received 23 31 2167 2175 O
prior 32 37 2176 2181 B-treatment
systemic 38 46 2182 2190 I-treatment
therapy 47 54 2191 2198 I-treatment
for 55 58 2199 2202 O
PTCL 59 63 2203 2207 B-cancer
( 64 65 2208 2209 O
except 65 71 2209 2215 O
for 72 75 2216 2219 O
corticosteroids 76 91 2220 2235 B-treatment
for 92 95 2236 2239 O
10 96 98 2240 2242 B-upper_bound
or 99 101 2243 2245 O
fewer 102 107 2246 2251 O
days 108 112 2252 2256 O
at 113 115 2257 2259 O
any 116 119 2260 2263 O
dose 120 124 2264 2268 O
, 124 125 2268 2269 O
no 126 128 2270 2272 O
washout 129 136 2273 2280 O
period 137 143 2281 2287 O
required 144 152 2288 2296 O
as 153 155 2297 2299 O
long 156 160 2300 2304 O
as 161 163 2305 2307 O
they 164 168 2308 2312 O
discontinue 169 180 2313 2324 O
prior 181 186 2325 2330 O
to 187 189 2331 2333 O
starting 190 198 2334 2342 O
study 199 204 2343 2348 O
therapy 205 212 2349 2356 O
) 212 213 2356 2357 O

Patients 0 8 2358 2366 O
receiving 9 18 2367 2376 O
ongoing 19 26 2377 2384 B-treatment
treatment 27 36 2385 2394 I-treatment
with 37 41 2395 2399 O
any 42 45 2400 2403 O
other 46 51 2404 2409 O
investigational 52 67 2410 2425 B-treatment
agents 68 74 2426 2432 I-treatment

Patients 0 8 2433 2441 O
who 9 12 2442 2445 O
are 13 16 2446 2449 O
pregnant 17 25 2450 2458 B-pregnancy
or 26 28 2459 2461 O
actively 29 37 2462 2470 O
nursing 38 45 2471 2478 O
an 46 48 2479 2481 O
infant 49 55 2482 2488 O

Patients 0 8 2489 2497 O
who 9 12 2498 2501 O
have 13 17 2502 2506 O
known 18 23 2507 2512 O
central 24 31 2513 2520 O
nervous 32 39 2521 2528 O
system 40 46 2529 2535 O
( 47 48 2536 2537 O
CNS 48 51 2537 2540 O
) 51 52 2540 2541 O
involvement 53 64 2542 2553 O
of 65 67 2554 2556 O
lymphoma 68 76 2557 2565 B-cancer

Patients 0 8 2566 2574 O
who 9 12 2575 2578 O
received 13 21 2579 2587 O
chemotherapy 22 34 2588 2600 B-treatment
( 35 36 2601 2602 O
including 36 45 2602 2611 O
monoclonal 46 56 2612 2622 B-treatment
antibodies 57 67 2623 2633 I-treatment
) 67 68 2633 2634 O
or 69 71 2635 2637 O
radiotherapy 72 84 2638 2650 B-treatment
, 84 85 2650 2651 O
administered 86 98 2652 2664 O
for 99 102 2665 2668 O
any 103 106 2669 2672 O
condition 107 116 2673 2682 O
, 116 117 2682 2683 O
within 118 124 2684 2690 O
4 125 126 2691 2692 B-upper_bound
weeks 127 132 2693 2698 I-upper_bound
prior 133 138 2699 2704 I-upper_bound
to 139 141 2705 2707 O
registration 142 154 2708 2720 O
are 155 158 2721 2724 O
not 159 162 2725 2728 O
eligible 163 171 2729 2737 O

Patients 0 8 2738 2746 O
who 9 12 2747 2750 O
received 13 21 2751 2759 O
prior 22 27 2760 2765 O
exposure 28 36 2766 2774 O
to 37 39 2775 2777 O
any 40 43 2778 2781 O
other 44 49 2782 2787 B-treatment
histone 50 57 2788 2795 I-treatment
deacetylase 58 69 2796 2807 I-treatment
( 70 71 2808 2809 I-treatment
HDAC 71 75 2809 2813 I-treatment
) 75 76 2813 2814 I-treatment
inhibitors 77 87 2815 2825 I-treatment
or 88 90 2826 2828 O
immunomodulatory 91 107 2829 2845 B-treatment
( 108 109 2846 2847 I-treatment
IMID 109 113 2847 2851 I-treatment
) 113 114 2851 2852 I-treatment
agents 115 121 2853 2859 I-treatment
for 122 125 2860 2863 O
any 126 129 2864 2867 O
reason 130 136 2868 2874 O

Patients 0 8 2875 2883 O
with 9 13 2884 2888 O
a 14 15 2889 2890 O
QT 16 18 2891 2893 B-clinical_variable
interval 19 27 2894 2902 I-clinical_variable
> 28 29 2903 2904 O
500 30 33 2905 2908 B-lower_bound
msec 34 38 2909 2913 I-lower_bound
( 39 40 2914 2915 O
using 40 45 2915 2920 O
the 46 49 2921 2924 O
Bazett 50 56 2925 2931 O
's 56 58 2931 2933 O
formula 59 66 2934 2941 O
) 66 67 2941 2942 O
within 68 74 2943 2949 O
28 75 77 2950 2952 B-upper_bound
days 78 82 2953 2957 I-upper_bound
prior 83 88 2958 2963 I-upper_bound
to 89 91 2964 2966 O
registration 92 104 2967 2979 O

Patients 0 8 2980 2988 O
with 9 13 2989 2993 O
a 14 15 2994 2995 O
known 16 21 2996 3001 O
human 22 27 3002 3007 B-chronic_disease
immunodeficiency 28 44 3008 3024 I-chronic_disease
( 45 46 3025 3026 I-chronic_disease
HIV 46 49 3026 3029 I-chronic_disease
) 49 50 3029 3030 I-chronic_disease
infection 51 60 3031 3040 O

Patients 0 8 3041 3049 O
with 9 13 3050 3054 O
adequate 14 22 3055 3063 O
archived 23 31 3064 3072 O
( 32 33 3073 3074 O
well 33 37 3074 3078 O
- 37 38 3078 3079 O
preserved 38 47 3079 3088 O
, 47 48 3088 3089 O
formalin 49 57 3090 3098 O
- 57 58 3098 3099 O
fixed 58 63 3099 3104 O
) 63 64 3104 3105 O
biopsy 65 71 3106 3112 B-treatment
tissue 72 78 3113 3119 O
remaining 79 88 3120 3129 O
will 89 93 3130 3134 O
be 94 96 3135 3137 O
required 97 105 3138 3146 O
to 106 108 3147 3149 O
submit 109 115 3150 3156 O
a 116 117 3157 3158 O
portion 118 125 3159 3166 O
for 126 129 3167 3170 O
exploratory 130 141 3171 3182 O
studies 142 149 3183 3190 O

Patients 0 8 3191 3199 O
with 9 13 3200 3204 O
marrow 14 20 3205 3211 B-chronic_disease
- 20 21 3211 3212 I-chronic_disease
only 21 25 3212 3216 I-chronic_disease
disease 26 33 3217 3224 I-chronic_disease

Peripheral 0 10 3225 3235 B-cancer
T 11 12 3236 3237 I-cancer
- 12 13 3237 3238 I-cancer
cell 13 17 3238 3242 I-cancer
lymphoma 18 26 3243 3251 I-cancer
, 26 27 3251 3252 O
unspecified 28 39 3253 3264 O
( 40 41 3265 3266 O
not 41 44 3266 3269 O
otherwise 45 54 3270 3279 O
specified 55 64 3280 3289 O
[ 65 66 3290 3291 O
NOS 66 69 3291 3294 O
] 69 70 3294 3295 O
) 70 71 3295 3296 O

Platelets 0 9 3297 3306 B-clinical_variable
> 10 11 3307 3308 O
= 11 12 3308 3309 O
50,000 13 19 3310 3316 B-lower_bound
/ 19 20 3316 3317 I-lower_bound
mcl 20 23 3317 3320 I-lower_bound

Precursor 0 9 3321 3330 B-cancer
T 10 11 3331 3332 I-cancer
- 11 12 3332 3333 I-cancer
lymphoblastic 12 25 3333 3346 I-cancer
lymphoma 26 34 3347 3355 I-cancer
/ 34 35 3355 3356 O
leukemia 35 43 3356 3364 B-cancer

Psychiatric 0 11 3365 3376 B-chronic_disease
illness 12 19 3377 3384 I-chronic_disease
/ 19 20 3384 3385 O
social 20 26 3385 3391 O
situations 27 37 3392 3402 O
that 38 42 3403 3407 O
would 43 48 3408 3413 O
limit 49 54 3414 3419 O
compliance 55 65 3420 3430 O
with 66 70 3431 3435 O
study 71 76 3436 3441 O
requirements 77 89 3442 3454 O

Subcutaneous 0 12 3455 3467 B-cancer
panniculitis 13 25 3468 3480 I-cancer
- 25 26 3480 3481 I-cancer
like 26 30 3481 3485 I-cancer
T 31 32 3486 3487 I-cancer
- 32 33 3487 3488 I-cancer
cell 33 37 3488 3492 I-cancer
lymphoma 38 46 3493 3501 I-cancer

Symptomatic 0 11 3502 3513 O
congestive 12 22 3514 3524 B-chronic_disease
heart 23 28 3525 3530 I-chronic_disease
failure 29 36 3531 3538 I-chronic_disease

T 0 1 3539 3540 B-cancer
- 1 2 3540 3541 I-cancer
cell 2 6 3541 3545 I-cancer
granular 7 15 3546 3554 I-cancer
lymphocytic 16 27 3555 3566 I-cancer
leukemia 28 36 3567 3575 I-cancer

T 0 1 3576 3577 B-cancer
- 1 2 3577 3578 I-cancer
cell 2 6 3578 3582 I-cancer
prolymphocytic 7 21 3583 3597 I-cancer
leukemia 22 30 3598 3606 I-cancer

Total 0 5 3607 3612 B-clinical_variable
bilirubin 6 15 3613 3622 I-clinical_variable
= 16 17 3623 3624 O
< 17 18 3624 3625 O
2 19 20 3626 3627 B-upper_bound
x 21 22 3628 3629 I-upper_bound
upper 23 28 3630 3635 I-upper_bound
limit 29 34 3636 3641 I-upper_bound
normal 35 41 3642 3648 I-upper_bound
( 42 43 3649 3650 I-upper_bound
ULN 43 46 3650 3653 I-upper_bound
) 46 47 3653 3654 I-upper_bound

Transformed 0 11 3655 3666 O
mycosis 12 19 3667 3674 B-cancer
fungoides 20 29 3675 3684 I-cancer

Unstable 0 8 3685 3693 B-chronic_disease
angina 9 15 3694 3700 I-chronic_disease
pectoris 16 24 3701 3709 I-chronic_disease

all 0 3 3710 3713 O
patients 4 12 3714 3722 O
must 13 17 3723 3727 O
agree 18 23 3728 3733 O
to 24 26 3734 3736 O
undergo 27 34 3737 3744 O
counseling 35 45 3745 3755 B-treatment
sessions 46 54 3756 3764 I-treatment
every 55 60 3765 3770 O
28 61 63 3771 3773 B-upper_bound
days 64 68 3774 3778 I-upper_bound
about 69 74 3779 3784 O
pregnancy 75 84 3785 3794 B-pregnancy
precautions 85 96 3795 3806 O
and 97 100 3807 3810 O
risks 101 106 3811 3816 O
of 107 109 3817 3819 O
fetal 110 115 3820 3825 O
exposure 116 124 3826 3834 O

anaplastic 0 10 3835 3845 B-cancer
large 11 16 3846 3851 I-cancer
cell 17 21 3852 3856 I-cancer
kinase 22 28 3857 3863 I-cancer
( 29 30 3864 3865 I-cancer
ALK)-negative 30 43 3865 3878 I-cancer

currently 0 9 3879 3888 O
treated 10 17 3889 3896 O
squamous 18 26 3897 3905 B-cancer
cell 27 31 3906 3910 I-cancer
and 32 35 3911 3914 O
basal 36 41 3915 3920 B-cancer
cell 42 46 3921 3925 I-cancer
carcinoma 47 56 3926 3935 I-cancer
of 57 59 3936 3938 I-cancer
the 60 63 3939 3942 I-cancer
skin 64 68 3943 3947 I-cancer
, 68 69 3947 3948 O
carcinoma 70 79 3949 3958 B-cancer
in 80 82 3959 3961 I-cancer
situ 83 87 3962 3966 I-cancer
of 88 90 3967 3969 I-cancer
the 91 94 3970 3973 I-cancer
cervix 95 101 3974 3980 I-cancer
, 101 102 3980 3981 O
breast 103 109 3982 3988 B-cancer
, 109 110 3988 3989 O
or 111 113 3990 3992 O
bladder 114 121 3993 4000 B-cancer
, 121 122 4000 4001 O
or 123 125 4002 4004 O
surgically 126 136 4005 4015 O
removed 137 144 4016 4023 O
melanoma 145 153 4024 4032 B-cancer
in 154 156 4033 4035 I-cancer
situ 157 161 4036 4040 I-cancer
of 162 164 4041 4043 I-cancer
the 165 168 4044 4047 I-cancer
skin 169 173 4048 4052 I-cancer
( 174 175 4053 4054 O
stage 175 180 4054 4059 O
0 181 182 4060 4061 O
) 182 183 4061 4062 O
with 184 188 4063 4067 O
histologically 189 203 4068 4082 O
confirmed 204 213 4083 4092 O
free 214 218 4093 4097 O
margins 219 226 4098 4105 O
of 227 229 4106 4108 O
excision 230 238 4109 4117 O

these 0 5 4118 4123 O
topical 6 13 4124 4131 B-treatment
therapies 14 23 4132 4141 I-treatment
should 24 30 4142 4148 O
be 31 33 4149 4151 O
stopped 34 41 4152 4159 O
at 42 44 4160 4162 O
time 45 49 4163 4167 O
of 50 52 4168 4170 O
registration 53 65 4171 4183 O

topical 0 7 4184 4191 B-chronic_disease
treatment 8 17 4192 4201 I-chronic_disease
may 18 21 4202 4205 O
have 22 26 4206 4210 O
been 27 31 4211 4215 O
given 32 37 4216 4221 O
for 38 41 4222 4225 O
prior 42 47 4226 4231 O
existence 48 57 4232 4241 O
of 58 60 4242 4244 O
cutaneous 61 70 4245 4254 B-cancer
lymphoma 71 79 4255 4263 I-cancer
that 80 84 4264 4268 O
has 85 88 4269 4272 O
since 89 94 4273 4278 O
become 95 101 4279 4285 O
systemic 102 110 4286 4294 O
PTCL 111 115 4295 4299 B-cancer

transformed 0 11 4300 4311 O
Mycosis 12 19 4312 4319 B-cancer
fungoides 20 29 4320 4329 I-cancer
[ 30 31 4330 4331 I-cancer
MF 31 33 4331 4333 I-cancer
] 33 34 4333 4334 I-cancer

with 0 4 4335 4339 O
a 5 6 4340 4341 O
cumulative 7 17 4342 4352 B-clinical_variable
illness 18 25 4353 4360 I-clinical_variable
rating 26 32 4361 4367 I-clinical_variable
scale 33 38 4368 4373 I-clinical_variable
( 39 40 4374 4375 I-clinical_variable
CIRS 40 44 4375 4379 I-clinical_variable
) 44 45 4379 4380 I-clinical_variable
score 46 51 4381 4386 I-clinical_variable
> 52 53 4387 4388 O
= 53 54 4388 4389 O
6 55 56 4390 4391 B-lower_bound
OR 57 59 4392 4394 O
deemed 60 66 4395 4401 O
ineligible 67 77 4402 4412 O
for 78 81 4413 4416 O
cytotoxic 82 91 4417 4426 B-treatment
chemotherapy 92 104 4427 4439 I-treatment
by 105 107 4440 4442 O
the 108 111 4443 4446 O
treating 112 120 4447 4455 O
investigator 121 133 4456 4468 O

